REMSpace Closes $1M Seed Round for Lucid Dreaming Technology Development
The funding will support the CEO’s vision to make lucid dreaming accessible to the masses.
The funding will support the CEO’s vision to make lucid dreaming accessible to the masses.
Research involving 67 subjects who participated in over 7,772 sleep sessions demonstrated that 73% experienced notable improvements in their sleep, with enhancements in the depth and overall quality of sleep noted.
A $2m funding round will accelerate the company's product development and regulatory and precommercialization efforts as it prepares for a 2024 entry into the North American CPAP market.
A Dongguan, China-based sleep technology brand launched a new smart sleep line of artificial intelligence (AI)-powered mattresses, pillows, and beds.
Read MoreNyxoah SA has partnered with ResMed Germany to increase OSA awareness and therapy penetration in the German market.
Read MoreMount Sinai’s newly developed ventilatory burden offers a potentially more effective alternative to the traditional AHI in assessing severity in sleep apnea patients.
Read MoreResearchers from the California-based startup REMspace have achieved the real-time transmission of melodies from lucid dreams using electromyography sensors.
Read MoreNyxoah announced operating results for the second quarter and first half of 2023, emphasizing advances in its investigational device exemption trial designed to support the marketing authorization of the Genio neurostimulator system for the treatment of OSA.
Read MoreThe company has completed all 115 implants in the DREAM trial and expects full 12-month data in the first quarter of next year.
Read MoreProceeds from the financing round will be used in part to finish the pivotal trial for aerSleep II and file for FDA market clearance.
Read MoreAn interim update highlights the initial treatment benefits for subjects who successfully acclimated to wearing the device and exhibited a response to the single vacuum pressure being tested.
Read MoreThe Belgium-based company plans to launch its chin patch home sleep test in the US after receiving FDA clearance and closing a €17 million funding round.
Read MoreThe clinical and regulatory milestones bring Nyxoah closer to offering its Genio neurostimulator solution to OSA patients in the US, according to the company.
Read MoreBioscience Association Manitoba unveiled four winners, including Cerebra, to be honored at its Annual Awards Dinner on March 2. Here’s which award Cerebra is picking up.
Read MoreSommetrics is advancing activities aimed at obtaining US Food and Drug Administration (FDA) market clearance for its flagship product, aerSleep II, which is targeted for the treatment of obstructive sleep apnea in those unable to use CPAP therapy.
Read MoreAstronauts find it difficult to maintain a natural circadian rhythm and generally complain about their sleep. A new project will examine the differences between human sleep patterns on earth and in space using an ear EEG.
Read MoreGenio 2.1’s upgrades are entirely related to the external components of the Genio system, as the implantable stimulator remains unchanged.
Read MoreX-trodes raised $4.5 million in funding in October 2021, and is now pursuing approval for the technology from the US Food and Drug Administration. If that goes well, the company hopes to start selling the device to sleep clinics in 2023.
Read More